This trial is evaluating the addition of a targeted cancer drug (Magrolimab) to chemotherapy (using Nab-Paclitaxel or Paclitaxel) for the treatment of people with triple negative breast cancer that has spread to other parts of the body.
This trial is treating patients with triple negative breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer
Commercial Sponsor
Gilead Sciences
Summary
Eligible participants will include a safety run-in cohort to establish a recommended phase two dose (RP2D) of Magrolimab. Following the safety run-in cohort, eligible participants will be randomised into one of two experimental treatment arms. Participants in one arm will receive the RP2D of Magrolimab in combination with Nab-Paclitaxel (100mg/m^2) or Paclitaxel (90mg/m^2) on Days 1, 8 and 15 of each 28-day treatment cycle. Participants in the other arm won't receive treatment with Magrolimab.
Recruiting Hospitals Read More